CENTER OF EXCELLENCE IN DIABETES AND OBESITY RESEARCH: PROJECT 5

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 阐明miR-301a在高血糖损伤和继发性糖尿病并发症中的作用是本项目的主要重点。我们提出了三个目标：目的1研究miR-301a在正常或高糖培养的SMC增殖和迁移中的作用，并确定miR-301a在糖尿病和非糖尿病小鼠颈动脉损伤中是否过度表达。目的#2将描述高血糖和核因子-kappaB调节miR-301a表达的分子机制。目的#3将确定抑制miR-301a的表达是否能阻止原位SMC的过度增殖。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Elucidation of the roles of miR-301a in hyperglycemic injury and secondary diabetic complications is the main focus of this project. We have proposed three aims: Aim #1 will examine the role of miR-301a in proliferation and migration of SMC cultured in the presence of normal or high glucose and determine whether miR-301a is over expressed in injured carotid artery of diabetic and non-diabetic mice. Aim #2 will delineate the molecular mechanism by which hyperglycemia and NF-kappaB regulates the expression of miR-301a. Aim #3 will determine whether repressing miR-301a expression prevents hyperproliferation of SMC in situ.